Loading stock data…
CTKB
$4.13+0.09 (+2.23%)
After Hours$4.22+0.09 (+2.18%)· Last close Jun 9
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytek Biosciences, Inc. in the Healthcare sector is trading at $4.13. Wall Street consensus targets $5.69 (4 analysts), implying a +37.7% move over the next 12 months. The stock is currently 33% below its 52-week high of $6.18, remaining 7.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +37.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.13
Potential Downside
0%
Whystock Fair Value$4.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.59%
Volume
Today's trading volume
1.34M
Recent News
Promising Penny Stocks To Consider In June 2026
The market has climbed 1.6% in the last 7 days, contributing to a remarkable 28% increase over the past year, with earnings expected to grow by 17% per annum in the coming years. Though 'penny stock' might sound like a relic of past trading days, it still points to opportunities in smaller or newer companies that can offer significant returns when built on solid financials. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, offering...
Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder
By Karen Roman Prenetics Global Limited (Nasdaq: PRE) confirmed its multi-year partnership with #1 New York Times bestselling author and award-winning podcast host of On Purpose, Jay Shetty, making him […]
Cytek (CTKB) Q1 2026 Earnings Call Transcript
Earlier today, Cytek Biosciences released financial results for the first quarter ended March 31, 2026. A copy of the news release is also available on the Investor Relations section of Cytek's website at investors.cytekbio.com. Joining me today from Cytek are Wenbin Jiang, CEO; and Bill McCombe, CFO.
Cytek Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of Cytek Biosciences, Inc.'s Q1 2026 earnings call
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?